Matthew Shahbandi, MD
Urology · Bloomfield, NJNPI 1912969379
Payments from drug & device makers
Across 152 payments — averaging $59.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acerus Pharmaceuticals Corporation$4K
- Boston Scientific$1K
- Procept Biorobotics Corporation$756
- Antares Pharma, Inc.$493
- Coloplast$477
- Olympus America Inc.$183
- plus $2K from 29 others
What the payments were for
- Consulting fees$3,85042%
- Travel & lodging$1,52017%
- Food & beverage$3,67740%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acerus Pharmaceuticals Corporation | 3 | $4,199 |
| Boston Scientific | 13 | $1,203 |
| Procept Biorobotics Corporation | 8 | $756 |
| Antares Pharma, Inc. | 32 | $493 |
| Coloplast | 21 | $477 |
| Olympus America Inc. | 3 | $183 |
| Astellas Pharma US Inc | 9 | $179 |
| Neotract Inc. | 1 | $164 |
| Immunitybio, Inc. | 1 | $162 |
| Sumitomo Pharma America, Inc. | 2 | $141 |
| Pfizer | 9 | $121 |
| Urogen Pharma, Inc. | 1 | $114 |
| SRS Medical Systems, Inc. | 1 | $104 |
| Blue Earth Diagnostics | 1 | $98 |
| Bayer | 6 | $95 |
| Endo Pharmaceuticals Inc. | 5 | $77 |
| Tolmar Pharmaceuticals, Inc. | 6 | $74 |
| Clarus Therapeutics Inc. | 5 | $66 |
| 180 Medical, Inc. | 2 | $37 |
| Tolmar, Inc. | 2 | $36 |
| Myovant Sciences Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $31 |
| Dendreon Pharmaceuticals LLC | 2 | $30 |
| Amgen | 2 | $30 |
| AbbVie | 2 | $27 |
| Ferring Pharmaceuticals Inc. | 2 | $27 |
| Seapearl East, Inc | 1 | $19 |
| Merck | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $15 |
| Axonics, Inc. | 1 | $15 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $12 |
| Verity Pharmaceuticals Inc. | 1 | $12 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Natesto$4,187
- AquaBeam Robotic System$596
- GENERAL BPH$448
- GENERAL KIDNEY STONE DISEASE$408
- TITAN$206
- UroLift$164
- ANKTIVA$162
- iTIND System$146
- rezum Generator$143
- GEMTESA$120
- JELMYTO$114
- Spanner Prothetic Stent$104
How this compares
$9,088 in reported general payments places this provider in the 75th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 24 | $66,955 |
| MyrbetriqMirabegron | 109 | $59,681 |
| GemtesaVibegron | 50 | $34,096 |
| Tamsulosin Hcl | 736 | $14,652 |
| XyostedTestosterone Enanthate | 16 | $9,307 |
| Oxybutynin Chloride ErOxybutynin Chloride | 251 | $7,085 |
| Mirabegron ErMirabegron | 13 | $6,120 |
| Methenamine Hippurate | 65 | $4,982 |
| Finasteride | 290 | $4,280 |
| CefuroximeCefuroxime Axetil | 195 | $2,379 |
| Testosterone | 17 | $1,944 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 49 | $1,516 |
| Bicalutamide | 41 | $1,440 |
| Solifenacin Succinate | 48 | $1,352 |
| Tadalafil | 50 | $1,179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $141 | $101,05174 claims |
| Astellas Pharma US IncMyrbetriq | $179 | $59,681109 claims |
| Antares Pharma, Inc.Xyosted | $493 | $9,30716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 401 urology providers in New Jersey.
Other urology in Bloomfield
- Gordon BrownCherry Hill$2.8M
- Nitin YerramHackensack$1.6M
- Michael StifelmanHackensack$1.5M
- Thomas MuellerLinwood$1.2M
- David SussmanLinwood$833K
- Michael IngberDenville$607K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$464K
- Neil ShermanCranford$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.